Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
Any management considerations with respect to disease etiology?
Related Questions
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
What patient factors guide your selection of maintenance therapies for a patient with auto-immune hepatitis?
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
What kind of follow up or monitoring do you recommend for patients with at risk alpha-1-anti-trypsin phenotypes?
How would you approach a referral for concern for hemochromatosis with ferritin elevation but otherwise normal iron studies?
For how long would you treat a patient with latent TB before allowing them to proceed with a liver transplant?
What is your endoscopic approach to the management of refractory GAVE in persistently anemic patients?
Do you find there is any benefit to giving N-acetyl-cysteine in non-acetaminophen related acute liver failure?